Investment Banking

Eason Hahm Quoted in Reuters

William Blair biotech investment banking director Eason Hahm was quoted in a Reuters story centered on biotech M&A activity in 2026.

“Over $300 billion of revenue in the sector faces LOEs in the next five years,” Hahm told the publication.

Our Latest News

Tuesday, November 3, 2026

The Leveraged Finance Market Navigates the Changing Seasons

2026 has been a year of multifaceted uncertainty for borrowers and lenders across the leveraged finance market—but conditions have improved from early-year lows, settling into a trend of solid issuance volume and borrower-friendly pricing.
Read more
Wednesday, October 28, 2026

Vexcel Has Agreed to Be Acquired by CoStar Group

William Blair acted as the exclusive financial advisor to Vexcel Group, Inc. in connection with its pending sale to CoStar Group, Inc. (NASDAQ: CSGP).
Read more
Tuesday, October 20, 2026

Morgan Stanley Capital Partners Has Acquired The Rapid Group

William Blair acted as the exclusive financial advisor to Morgan Stanley Capital Partners in connection with the acquisition of The Rapid Group.
Read more

See more news

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures